Belantamab mafodotin

• CAT Number: I042545
• CAS Number: 2050232-20-5
• Purity: ≥95%

Belantamab mafodotin (GSK2857916) is composed of humanized and focused monoclonal antibody against B cell maturation antigen (BCMA) and McMMAF. Belantamab mafodotin has anti-myeloma activity[1][2].
Belantamab mafodotin binds to human BCMA protein with a Kd of 1 nM[2].
Belantamab mafodotin induces G2/M arrest in multiple myeloma cells in a dose and time dependent manner[2].
Belantamab mafodotin signifcantly promotes phagocytosis of multiple myeloma cells by human macrophages derived from macrophage colony-stimulating factor-stimulated monocytes[2].
Belantamab mafodotin signifcantly improves survival compared to vehicle in mice harbouring OPM2 tumours[2].

Reference

[1]. Hulin C, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020 Feb;21(2):207-221.
 [Content Brief]

[2]. Markham A. Belantamab Mafodotin: First Approval. Drugs. 2020 Oct;80(15):1607-1613.
 [Content Brief]